Johnson & Johnson raised U.S. list prices of about two dozen drugs, including some of its top-selling products, Reuters reported.
According to the report, data from Rx Savings Solutions, which sells software to help employers and health plans choose the least expensive medicines, indicated that most of the increases were between 6% and 7%.
Psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto are now among the hundreds of medicines to undergo price hikes at the start of 2019.
Johnson & Johnson said that although price increases on its medicines will average 4.2% in 2019, it expects to receive a lower net price for the therapies due to rebates and discounts it will negotiate with payers.
New Brunswick, N.J.-based J&J, the world's largest pharmaceutical company, has no plans to hike prices on any more drugs this year, according to spokesman Ernie Knewitz.